Department of Medicine, The Brooklyn Hospital Center, Clinical Affiliate of The Mount Sinai Hospital, Brooklyn, New York, USA.
Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Clinical Affiliate of The Mount Sinai Hospital, Brooklyn, New York, USA.
Am J Gastroenterol. 2019 Sep;114(9):1496-1501. doi: 10.14309/ajg.0000000000000326.
Combined hepatocellular cholangiocarcinoma (CHC) is a rare form of primary liver cancer with features of hepatocellular carcinoma and cholangiocarcinoma. The objective of this study was to investigate the incidence, demographics, tumor characteristics, treatment, and survival of patients with CHC.
Data on CHC between 2004 and 2014 were extracted from the Surveillance, Epidemiology, and End Results Registry and analyzed.
Five hundred twenty-nine patients with CHC were identified; 367 were male. Median age at diagnosis was 62.5 ± 12 years. The overall incidence of CHC between 2004 and 2014 was 0.05 per 100,000 per year. Incidence increased with age, with the highest incidence in men occurring between 60 and 64 years and 75-79 years for women. Women had a higher incidence of CHC compared to men (0.08 vs 0.03 per 100,000 per year). Most tumors were poorly differentiated (30.8%) while the most common stage at presentation was stage 4 (26.8%). 39.5% of these tumors were resected while 6.8% received radiation and 34% received chemotherapy. One- and 5-year cause-specific survival for CHC was 41.9% and 17.7%, respectively, with a median survival of 8 months. Worse outcomes were noted among patients with tumor stage 3 (hazard ratio [HR] 2.03, 95% confidence interval [CI] 1.44-2.87, P = 0.000), stage 4 (HR 1.71, 95% CI 1.06-2.75, P = 0.027), those not treated with surgery (HR 4.94, 95% CI 3.64-6.68, P = 0.000), those who did not receive radiation (HR 1.71, 95% CI 1.08-2.70, P = 0.021), those who did not receive chemotherapy (HR 1.54, 95% CI 1.20-1.99, P = 0.001), and those with increasing tumor size on chemotherapy (HR 1.00, 95% CI 1.00-1.00, P = 0.013).
CHC is the combined presentation of 2 malignancies. Incidence appears to be increasing and is associated with age and male gender. While surgery, radiation, and chemotherapy are associated with improved outcomes, patients who did not undergo surgery are at highest risk for death.
肝细胞癌-胆管细胞癌(CHC)是一种罕见的原发性肝癌,具有肝细胞癌和胆管细胞癌的特征。本研究的目的是探讨 CHC 患者的发病率、人口统计学、肿瘤特征、治疗和生存情况。
从监测、流行病学和最终结果登记处提取了 2004 年至 2014 年间的 CHC 数据并进行了分析。
共确定了 529 例 CHC 患者,其中 367 例为男性。中位诊断年龄为 62.5±12 岁。2004 年至 2014 年间,CHC 的总体发病率为每年每 10 万人中 0.05 例。发病率随年龄增长而增加,男性发病率最高的年龄段为 60-64 岁和 75-79 岁,女性发病率最高的年龄段为 75-79 岁。女性 CHC 的发病率高于男性(每年每 10 万人中 0.08 比 0.03)。大多数肿瘤分化程度较差(30.8%),而最常见的分期为 4 期(26.8%)。39.5%的肿瘤接受了切除术,6.8%的肿瘤接受了放疗,34%的肿瘤接受了化疗。CHC 的 1 年和 5 年特异性生存率分别为 41.9%和 17.7%,中位生存时间为 8 个月。肿瘤分期为 3 期(危险比 [HR] 2.03,95%置信区间 [CI] 1.44-2.87,P=0.000)、4 期(HR 1.71,95% CI 1.06-2.75,P=0.027)、未接受手术治疗(HR 4.94,95% CI 3.64-6.68,P=0.000)、未接受放疗(HR 1.71,95% CI 1.08-2.70,P=0.021)、未接受化疗(HR 1.54,95% CI 1.20-1.99,P=0.001)和化疗期间肿瘤增大的患者(HR 1.00,95% CI 1.00-1.00,P=0.013)的预后更差。
CHC 是两种恶性肿瘤的联合表现。发病率似乎在增加,与年龄和男性性别有关。虽然手术、放疗和化疗与改善预后相关,但未行手术的患者死亡风险最高。